Astrazeneca buys tumour tech firm Definiens for $150m
4th Nov 2014 07:19
Drug giant Astrazeneca's research and development arm, Medimmune, has agreed to purchase imaging and data analysis technology company Definiens. Medimmune will pay $150m, together with additional pre-determined milestone payments. Definiens has developed a technology called tissue phenomics, which
Read moreAstrazeneca gains rights to Almirall respiratory franchise
3rd Nov 2014 07:10
Astrazeneca has gained the development and commercialisation rights to Almirall's respiratory franchise, giving it access to all on-market revenues, the drugs maker said. The group will pay an initial $875m, plus up to a further $1.22bn in development, launch and sales-related milestones. The deal,
Read moreLondon pre-open: Chinese PMI data to drag FTSE lower early on
2nd Nov 2014 17:33
Tracking a weaker session in Asia overnight, UK stocks are expected to begin a macro-focused week with small gains. City sources predict the FTSE 100 will open around nine points lower than Friday's close of 6,546.47. "As we approach a major week in the markets in terms of economic events, we are l
Read moreLondon open: Miners drag UK stocks lower, but Barclays gains
30th Oct 2014 08:34
London's stock exchange opened more or less flat on Thursday as heavy falls from mining stocks and BT offset gains from Barclays and St James's Place. The FTSE 100 was trading 0.1% lower at 6,449 in early deals. The subdued start follows a weak performance on Wall Street overnight as investors reac
Read moreAstrazeneca type 2 diabetes drug approved for use by US FDA
30th Oct 2014 07:48
Astrazeneca's Xigduo XR type 2 diabetes treatment has been approved for use in adults by the US Food and Drug Administration (FDA). The drug, which is already approved in Australia, is taken as a once-daily tablet that removes glucose from the body via the kidneys. "The addition of Xigduo XR to our
Read moreAstrazeneca's Olaparib treatment given thumbs up by European committee
24th Oct 2014 12:48
Friday brought good news for Astrazeneca shareholders after its Olaparib treatment was recommended for marketing authorisation by a European Medicines Agency (EMA) committee. The committee for Medicinal Products for Human Use (CHMP) gave the drug the thumbs-up for the treatment of women with BRCA-mu
Read moreMonday broker round-up UPDATE
13th Oct 2014 09:32
Amino Technologies: Northland Capital upgrades to buy with a target price of 100p. Anglo American: Canaccord Genuity initiates with a target price of 1720p and a buy recommendation. Credit Suisse upgrades to outperform with a target price of 1800p. Associated British Foods: Societe Generale upgrade
Read moreWoodford sells stake in Reckitt Benckiser
7th Oct 2014 18:12
Woodford Investment Management has added to its core holdings in British American Tobacco and G4S in its portfolio but announced it had sold down its stake in Reckitt Benckiser. Speaking about its decision to sell stakes in the multinational consumer goods company, which had been part of the fund fo
Read moreLondon midday: Mining gains offset by falls from airline, healthcare stocks
7th Oct 2014 11:36
Poor economic data was weighing on UK stocks on Tuesday, with decent gains in the mining sector offset by falls from airlines and pharmaceuticals. The FTSE 100 was trading 0.6% lower at 6,522 by around midday. Nervousness ahead of the start of third-quarter earnings season in the States was also ca
Read moreTuesday broker round-up UPDATE
7th Oct 2014 09:45
African Minerals: Canaccord Genuity lowers target price from 20p to 15p with a hold recommendation. Aggreko: Exane initiates with a target price of 1500p and an underperform rating. Amec: Liberum Capital cuts target price from 1035p to 908p staying with its sell recommendation. Antofagasta: Canacc
Read moreLondon open: UK stocks drop despite mining gains
7th Oct 2014 08:27
Strong gains in the UK mining sector weren't enough to keep London's FTSE 100 from slipping into the red on Tuesday morning. Indices across Europe were tracking a weak finish on Wall Street and a mixed performance on Asian markets overnight. The FTSE 100 was trading 0.6% lower at 6,526 within the o
Read moreLondon pre-open: Flat start predicted for FTSE
29th Sep 2014 07:42
London's blue chips are set to open flat on Monday morning ahead of a very busy week both at home and abroad, particularly in the latter half. City sources predict the FTSE 100 will open unchanged from Friday's close of 6,649. "European markets are set for an incredibly busy week as we see the f
Read moreAstrazeneca reports latest drug developments
29th Sep 2014 07:09
Drugs maker Astrazeneca has presented data from its pipeline of cancer treatment studies at the 2014 European Society of Medical Oncology Congress. The FTSE 100 group presented preliminary data from its ongoing phase I study of MEDI4736, which is being tested in combination with a drug called tre
Read moreLondon close: Stocks end with modest gain, but down on week overall
26th Sep 2014 16:48
UK stocks ended the final session of the week with a modest rise, although on the week the index was significantly lower. The FTSE 100 closed 9.68 points higher at 6,649.39. Markets are concerned about mounting geopolitical tensions, with the government due to take a vote on whether to participate
Read moreFTSE 100 movers: Easyjet shares take off thanks to comments from Jefferies
26th Sep 2014 16:23
Shares in Easyjet flew higher after Jefferies said the airline was situated to benefit from the recent problems with Air France-KLM, which has been forced to cancel numerous flights due to pilot strike action. The broker also predicted the group would have a positive finish to the year. Astrazeneca
Read more